Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2339${count})

  • Aligning Science Across Parkinson's, 2020
    The Genome-Microbiome Axis in the Cause of Parkinson Disease: Mechanistic Insights and Therapeutic Implications from Experimental Models and a Genetically Stratified Patient Population
    ASAP logo

    Study Rationale:
    Mutations in the gene for glucocerebrosidase (GBA) increase alpha-synuclein expression and are common in Parkinson's disease (PD). However, only about a third of people with GBA...

  • Aligning Science Across Parkinson's, 2020
    Co-Pathologies Drive Neuroinflammation and Progression in PD
    ASAP logo

    Study Rationale:
    While Parkinson’s disease (PD) is considered a synucleinopathy, the clinical progression of PD is driven by additional pathological proteins such as tau and beta-amyloid. Our...

  • Research Grant, 2020
    Discovery of Selective PET Imaging Agents for Tauopathies and Alpha-Synuclein

    Study Rationale:
    For reasons not yet understood, a protein called alpha-synuclein clumps in the brain cells of people with Parkinson’s disease. Some evidence suggests that a protein called tau also...

  • Research Grant, 2020
    Detecting Colonic Alpha-synuclein with an Antibody Specific for Disease-associated Forms as a Biomarker of Parkinson’s Disease

    Study Rationale:
    Despite several published studies using different anti-alpha-synuclein antibodies, to date no lab-based methods have been able to reliably identify Parkinson’s disease (PD) cases from...

  • Improved Biomarkers and Clinical Outcome Measures, 2020
    Quantification of S129 Phosphorylated Alpha-Synuclein Using the AlphaLISA Immunoassay Platform

    Study Rationale:
    In Parkinson's, there remains an unmet need for biomarkers to track disease progression and efficacy of potential therapies. This team of investigators is focused on fluid-based...

  • Improved Biomarkers and Clinical Outcome Measures, 2020
    PPMI DATIQ and SR T1w MRI Analysis

    Study Rationale:
    Parkinson’s disease results in functional and structural changes in the brain. Non-invasive imaging methods such as SPECT and MRI can measure these changes. The dopamine transporter...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.